Pharmacokinetic boosting of olaparib: Study protocol of a multicentre, open-label, randomised, non-inferiority trial (PROACTIVE-B)

Background: Pharmacokinetic (PK) boosting is the intentional use of a drug-drug interaction to enhance systemic drug exposure. PK boosting of the anticancer drug olaparib, a CYP3A-substrate, has the potential to reduce PK variability, side effects and financial burden associated with this drug. Afte...

Full description

Saved in:

Bibliographic Details
Main Authors:	Joanneke K. Overbeek, Niels A.D. Guchelaar, Ma Ida Mohmaed Ali, Muriëlle Sark, Carolien Hovenier, Wietske Kievit, Marjolijn J.L. Ligtenberg, Petronella B. Ottevanger, Haiko J. Bloemendal, Stijn L.W. Koolen, Ron H.J. Mathijssen, Ingrid A. Boere, Alwin D.R. Huitema, Gabe S. Sonke, Frans L. Opdam, Rob ter Heine, Nielka P. van Erp
Format:	Article
Language:	English
Published:	Elsevier 2025-06-01
Series:	Contemporary Clinical Trials Communications
Subjects:	Clinical trial Olaparib Cobicistat Pharmacokinetic boosting Non-inferiority
Online Access:	http://www.sciencedirect.com/science/article/pii/S2451865425000511
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Pharmacokinetic boosting of olaparib: Study protocol of a multicentre, open-label, randomised, non-inferiority trial (PROACTIVE-B)

Similar Items